Matt Trau is an ARC Australian Laureate Fellow. He is a Professor of Chemistry and Director of the Centre for Personalised Nanomedicine at the University of Queensland in Brisbane, Australia. He is also senior group leader and co-founder of the Australian Institute for Bioengineering and Nanotechnology (AIBN). His research is dedicated towards developing innovative nano-diagnostic and therapeutic approaches to help transform the healthcare system towards early detection and effective personalized treatment of disease. Since graduating from the University of Sydney (BSc Hons I, University Medal) and the University of Melbourne (PhD in Physical Chemistry), he has held positions within industry and academia across the globe. These include a Fulbright Research Fellowship at Princeton University, USA, a research scientist at Dow Chemical and ICI Pty Ltd. Matt has also been a visiting academic at The Dana Farber Cancer Research Institute, Harvard Medical School, Boston, and the Fred Hutchinson Cancer Research Centre, Seattle. Matt is internationally recognised for his innovative and cross-disciplinary research at the interface between chemistry, nanotechnology, biology and medicine. He has co-authored more than 300 publications, many of which appear in the highest impact journals in his field, e.g., eighteen Science and Nature family journal publications overall to date. His major awards and honours include an ARC Federation Fellowship (one of the most prestigious scientific Fellowships in Australia), a Fulbright Research Fellowship to the US, a "Young Tall Poppy" Award for Queensland, a UQ Foundation/Vice Chancellor's Research Excellence Award, a Paul Harris Fellowship, and a Pink Circle Award for breast cancer research excellence. Matt is passionate about science communication, has delivered more than 100 Plenary/keynote lectures at conferences around the world, a TEDx lecture (“An end to cancer mortality with Nanodiagnostics”) and frequently appears in the print, radio and television media on topics related to nanomedicine. His passion for research translation has led to the creation of 4 companies directly from technologies developed in his laboratory.